← Leaderboards
Martina Kovarova
Univ Of North Carolina Chapel Hill
$3,132,249
Attributed
$6,264,498
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2017–23$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$6,264,498 · 2
By mechanism
R01$6,264,498 · 2
Top collaborators
- Scott Parnell5 shared
- Soumya Rahima Benhabbour4 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Scott Parnell$6,933,513
- Soumya Rahima Benhabbour$11,411,217
- Angela Raquel Wahl$7,391,080
- Mackenzie Cottrell$6,158,418
- Robert Lipinski$4,791,248
Others in their field
Other Emerging Leaders on “Safety”
- Beth Baseler · Leidos Biomedical Research, Inc.$225,257,316
- Kimberly Smith · Ppd Development Lp$122,008,792
- Klaus Romero · Critical Path Institute$90,404,592
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$75,904,237
- Yunda Huang · Fred Hutchinson Cancer Center$70,809,823
- Leonard Freedman · Leidos Biomedical Research, Inc.$64,938,611
Research focus
SafetyToxic EffectHiv InfectionsRegimenPreventionPreventEvaluationHiv AntiretroviralMouse ModelIn VivoPharmaceutical PreparationsPharmacologyDoseDrug Delivery SystemsAdherenceDrug KineticsExperimental StudyFormulationAnimal ModelInjectableAnti-Retroviral AgentsInsightOralBase
Grant awards (9)
In vivo Evaluation of Safety and Pharmacology of the Sustained Release Formulation of Dolutegravir in Pre-Conception and Early Stages of Pregnancy in Animal Models$777,388
R01 · FY2023 · HD · contact PI
In vivo Evaluation of Safety and Pharmacology of the Sustained Release Formulation of Dolutegravir in Pre-Conception and Early Stages of Pregnancy in Animal Models$777,388
R01 · FY2022 · HD · contact PI
In vivo Evaluation of Safety and Pharmacology of the Sustained Release Formulation of Dolutegravir in Pre-Conception and Early Stages of Pregnancy in Animal Models$777,388
R01 · FY2021 · HD · contact PI
In vivo Evaluation of Safety and Pharmacology of the Sustained Release Formulation of Dolutegravir in Pre-Conception and Early Stages of Pregnancy in Animal Models$777,388
R01 · FY2020 · HD · contact PI
Development and pre-clinical evaluation of a novel Polymer-Based In-Situ Forming Implant (ISFI) for Long-Acting HIV PrEP$551,656
R01 · FY2020 · AI
In vivo Evaluation of Safety and Pharmacology of the Sustained Release Formulation of Dolutegravir in Pre-Conception and Early Stages of Pregnancy in Animal Models$777,388
R01 · FY2019 · HD · contact PI
Development and pre-clinical evaluation of a novel Polymer-Based In-Situ Forming Implant (ISFI) for Long-Acting HIV PrEP$558,250
R01 · FY2019 · AI
Development and pre-clinical evaluation of a novel Polymer-Based In-Situ Forming Implant (ISFI) for Long-Acting HIV PrEP$662,236
R01 · FY2018 · AI
Development and pre-clinical evaluation of a novel Polymer-Based In-Situ Forming Implant (ISFI) for Long-Acting HIV PrEP$605,416
R01 · FY2017 · AI